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Purpose: Chronic pain is often challenging to
address appropriately. Although patients with severe
chronic pain may respond to treatment with an opioid
analgesic, opioids are often associated with adverse
effects that may lead patients to disrupt or discontinue
therapy. In addition, opioid analgesics alone may not
be effective for all types of chronic pain, including
neuropathic pain. Tapentadol prolonged release (PR),
a centrally acting analgesic with 2 mechanisms of
action (μ-opioid receptor agonism and noradrenaline
reuptake inhibition), provides strong and reliable
analgesia across a range of indications, including
nociceptive, neuropathic, and mixed types of chronic
pain, and is associated with an improved tolerability
proﬁle relative to classic opioid analgesics. The pur-
pose of this article was to review the recent literature
on different aspects related to the clinical use of
tapentadol PR.
Methods: A review was conducted of the current
literature and relevant unpublished data on initiation
and titration of tapentadol PR, switching from classic
strong opioids, risk of withdrawal after discontinua-
tion, long-term treatment, coadministration with other
medications, and risk of abuse and diversion.
Findings: Tapentadol PR may provide clinically
meaningful beneﬁts over classic opioid analgesics,
including ease of initiating and titrating tapentadol
PR treatment in opioid-naive and opioid-experienced
patients, low risk of withdrawal after cessation of
tapentadol PR therapy, a favorable pharmacokinetic
proﬁle (allowing for coadministration with other
medications) of tapentadol PR, and low potential for
tapentadol PR abuse.
Implications: The broad analgesic efﬁcacy of ta-
pentadol PR may simplify chronic pain management
by allowing for the treatment of different types of pain94with a single analgesic. In addition, tapentadol is
associated with a low risk of pharmacokinetic inter-
actions, which permits its use in patients taking
multiple medications. Furthermore, the favorable tol-
erability proﬁle of tapentadol PR may result in
improved patient compliance and allow for easy
titration and rotation from previous strong opioids.
(Clin Ther. 2015;37:94–113) & 2015 The Authors.
Published by Elsevier HS Journals, Inc.
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Chronic pain is a common complaint, with a mean
prevalence of 27% in the general European adult
population.1 Chronic pain may have a negative effect
on physical function, mental health, day-to-day activ-
ities, and interpersonal relationships, and may be
associated with signiﬁcant costs related to lost work
days and increased health care utilization.1–3 The
negative effects of chronic pain on patients’ overall
health and well-being are compounded by poor pain
control, which is relatively common for patients with
chronic pain. In a 2006 survey of 4389 European
patients with chronic pain, 34% had severe pain and
40% felt that their pain was not adequately con-
trolled; furthermore, 450% of patients taking pre-
scription medications for their chronic pain felt thatVolume 37 Number 1
M.J. Sa´nchez del A´guila et al.these treatments were not effective or were only some-
what effective.3
The challenges associated with achieving adequate
pain management for patients with severe chronic
pain are manifold. Patients with severe chronic pain
may require treatment with an opioid analgesic, which
may provide effective analgesia for severe chronic pain
but may be associated with adverse effects (eg, nausea,
vomiting, constipation, and somnolence) that could
lead to the use of inadequate doses or to the dis-
ruption or discontinuation of therapy.4–7 Some
opioid-induced adverse effects, such as constipation,
may be refractory to standard treatments and may not
resolve with continued opioid treatment.8,9 Patients
may also develop tolerance to opioid analgesics over
time and may require higher doses to achieve adequate
analgesia,10 which may exacerbate tolerability issues.
Furthermore, the use of a single analgesic (eg, an
opioid) may be insufﬁcient to address mixed or neuro-
pathic chronic pain because nociceptive and neuro-
pathic types of chronic pain arise from different pain
mechanisms.11 The development of chronic pain in
general, and neuropathic pain in particular, seems to be
related to alterations in descending noradrenergic
modulation mechanisms11; thus, addressing mixed or
neuropathic pain may require the use of combination
therapy that addresses the ascending and descending
pain pathways.12,13 The use of combination therapy
with an opioid analgesic and a coanalgesic may be
associated with an increased risk of adverse effects or
treatment discontinuation in relation to monother-
apy.14,15 In addition, determining the correct balance
of doses of the opioid analgesic and coanalgesic to
optimize efﬁcacy and tolerability may pose a substan-
tial challenge, and patients may be less willing to
comply with treatment with multiple medications.
The use of a single analgesic that could address multi-
ple pain mechanisms while providing tolerable and
effective pain control for long-term treatment may
alleviate many of the problems associated with manag-
ing severe chronic pain.
Tapentadol represents a proposed new class of
centrally acting analgesics with 2 mechanisms of
action, μ-opioid receptor (MOR) agonism and nora-
drenaline reuptake inhibition (NRI),16,17 that contrib-
ute synergistically to its analgesic activity.18,19 Both
mechanisms of action reside in the parent compound;
thus, the analgesic activity of tapentadol is not reliant
on metabolic activation, and tapentadol has aJanuary 2015predictable and reliable pharmacokinetic proﬁle for
clinical use.20,21 By combining MOR agonism and
NRI in a single molecule, tapentadol may offer
improvements in efﬁcacy and tolerability compared
with classic opioid analgesics.17 In preclinical studies,
tapentadol was found to have a lower afﬁnity for the
MOR than was morphine.16,22 Despite this lower
afﬁnity for the MOR, clinical trials have reported
that tapentadol provides at least comparable pain
relief to other classic strong opioids (eg, oxyco-
done)23–30 because of the synergistic contribution of
NRI to its analgesic activity.31 The lower afﬁnity of
tapentadol for the MOR compared with classic opioid
analgesics may contribute to the reduction in opioid-
related adverse effects observed with tapentadol com-
pared with oxycodone.23–30
For patients with chronic pain who require long-
term analgesic treatment, prolonged-release (PR) an-
algesics allow for less frequent dosing and more
consistent pain management.32 The PR formulation
of tapentadol, which is taken twice daily, is approved
in Europe for the management of severe chronic pain
in adults, which can be adequately managed only with
opioid analgesics,33 and in the United States
(tapentadol extended release) for the management of
moderate to severe chronic pain in adults when a
continuous, around-the-clock opioid analgesic is
needed for an extended period.34 In the United
States, the extended-release formulation is also indi-
cated for pain associated with diabetic peripheral
neuropathy (DPN).34 Tapentadol PR, a World
Health Organization (WHO) step III analgesic, is a
scheduled substance in the United States and
Europe.33,35 Since 2010, PR formulations of tapenta-
dol have been launched in a variety of major Euro-
pean countries, the United States, Canada, and
Australia.
Tapentadol PR has been evaluated in patients with
severe or moderate to severe chronic low back
pain,24,29,36,37 osteoarthritis knee pain,23,29,38 pain
associated with DPN,39–41 and cancer-related pain,42–44
and has been found to provide strong and reliable
analgesia across a broad range of indications. Tapen-
tadol PR has also been associated with improvements
in neuropathic pain symptoms and quality of life in
patients with neuropathic pain,37,45 which are not con-
sistently observed with classic opioid treatments.46–51
The broad effectiveness of tapentadol PR for nocicep-
tive, neuropathic, and mixed types of chronic pain,95
Clinical Therapeuticswhich is likely due to its combination of MOR
agonism and NRI activities,18,19 may simplify chronic
pain treatment by eliminating the need to isolate and
treat the individual types of chronic pain with a
combination of different analgesics and coanalgesics.
Tapentadol PR may also facilitate chronic pain man-
agement because tapentadol is associated with a low
risk of pharmacokinetic interactions,20,21 making it a
viable option for poly-medicated patients, including
elderly patients. In addition, the favorable tolerability
proﬁle of tapentadol PR23,24,29 relative to classical
opioid analgesics may be associated with improved
patient compliance, which, along with the low risk of
tolerance development observed over 1 year of treat-
ment,30 may allow for stable long-term dosing and
consistent analgesia. Furthermore, the relatively low
risk of adverse effects associated with tapentadol PR
may allow for rapid up-titration, allowing patients to
achieve pain control more quickly. Thus, the integra-
tion of tapentadol PR as a ﬁrst option for patients
needing an opioid analgesic to control their pain, or as
an alternative for patients with inadequately managed
pain or intolerable adverse effects when taking an-
other opioid, may simplify chronic pain management
and improve patient outcomes. This article summa-
rizes various aspects of the practical handling of
tapentadol PR in a clinical setting, including the
established titration regimen for tapentadol PR, the
convenient conversion from other strong opioid an-
algesics to tapentadol PR, the efﬁcacy of the available
dose range for severe pain, the low potential of
withdrawal after discontinuation of tapentadol PR,
the use of tapentadol PR with concomitant medica-
tions, and the low potential for tapentadol PR abuse.
INITIATION, TITRATION, AND DOSING OF
TAPENTADOL PR TREATMENT
Initiation, Titration, and Dosing of Tapentadol
PR in the General Population With Chronic Pain
Achieving adequate pain control rapidly while
minimizing intolerable adverse effects is a goal for
many patients with chronic pain initiating a new
analgesic regimen. For patients with severe chronic
pain who are treated with an opioid analgesic, low
starting doses and slow upward titration are recom-
mended to minimize the risk of opioid-related adverse
events.52,53 This cautious approach is warranted be-
cause opioid analgesics may be associated with po-
tential severe adverse effects that may be exacerbated96by rapid increases in doses.53 Opioid-naive patients
are particularly at risk for early adverse effects (eg,
nausea and vomiting) and are more vulnerable to the
rare, but serious, tolerability issue of respiratory
depression.7,54 With a slow titration schedule, how-
ever, patients may experience delays in achieving
adequate analgesia. Furthermore, patients may be
unable to use sufﬁcient doses of opioid analgesics to
achieve adequate pain control owing to the occurrence
of intolerable adverse effects.4–7
Tapentadol PR has been associated with improved
tolerability (speciﬁcally, lower incidences of nausea,
vomiting, dizziness, and constipation) relative to the
classic opioid analgesics oxycodone controlled release
(CR)23,24,29,30 and morphine CR.42 In a randomized
placebo- and active-controlled study of tapentadol PR
for the management of moderate to severe chronic low
back pain, the odds of experiencing constipation or
the composite of nausea and vomiting was signiﬁ-
cantly lower with tapentadol PR than with oxycodone
CR (Po 0.001 for both comparisons).24 In that same
study, the incidence of the central nervous system
(CNS)–related adverse event of dizziness was
signiﬁcantly lower with tapentadol PR than with
oxycodone CR (Po 0.05).55 The rate of discontinua-
tions due to any CNS-related adverse event was also
numerically lower with tapentadol PR (6.2%) than
with oxycodone CR (14.0%).24 Although patients
often develop tolerance to these adverse effects with
continuing opioid treatment, the occurrence of nausea
and vomiting early in the course of therapy may
reduce patient adherence to treatment4,5,7 or may
delay increases in analgesic doses, resulting in inad-
equate analgesia. Furthermore, tapentadol PR has also
been associated with a reduction in the occurrence of
adverse effects that typically do not resolve with
continued opioid treatment (eg, constipation) relative
to other opioids,23,24,29 which may improve quality of
life for patients undergoing long-term therapy. The
improved tolerability proﬁle, particularly the im-
proved gastrointestinal tolerability proﬁle, of tapenta-
dol PR may allow for relatively rapid up-titration of
doses and the use of higher doses (up to 500 mg/d),
which may allow patients to achieve effective pain
control more rapidly.
In opioid-naive patients, the recommended starting
dose of tapentadol PR is 50 mg BID (approximately
every 12 hours), and that dose should be individually
titrated to the dose within the range of 50 to 250 mgVolume 37 Number 1
Treatment Initiation
Opioid-naive patients
Starting dose: 50 mg BID
Opioid-experienced patients
Starting dose based on previous
analgesic type and dose
Titration
Individually titrate dose in
increments of 50 mg BID
every 3 d to reach the
dose providing an optimal
balance of pain management
and tolerability
Reassess pain
after 3 d and
adjust dose if
necessary
Maintenance Therapy
Maintain patients on one of
the following doses:
50 mg BID
100 mg BID
150 mg BID
200 mg BID
250 mg BID
Figure 1. Titration and dosing recommendations for tapentadol prolonged release.
M.J. Sa´nchez del A´guila et al.BID that provides an optimal balance of analgesic
efﬁcacy and tolerability (Figure 1).33 For patients who
are currently taking opioid analgesics, the recommended
starting dose of tapentadol PR depends on the type and
daily dose of the previous opioid. A titration regimen in
which twice-daily doses of tapentadol PR are increased
by 50 mg BID every 3 days is appropriate for most
patients to achieve adequate pain control.33 A more
rapid titration schedule may be considered for patients
with uncontrolled pain.37,38,45,56 The recommended
dose range of tapentadol PR is 50 to 250 mg BID; daily
doses of 4500 mg of tapentadol PR are not recom-
mended.33 Tapentadol PR is available in 50-, 100-, 150-,
200-, and 250-mg dose strengths.33 A 25-mg tapentadol
PR tablet formulation, currently available in Spain, may
offer a future option for ﬁner dose adjustments up to
250 mg BID in patients with a potential higher sensi-
tivity to the analgesic effects of tapentadol PR (eg,
elderly patients, patients with hepatic impairment).
The easy and reliable titration schedule and the use
of doses within the recommended dose range are
supported by the results of 4 key Phase III studies of
tapentadol PR in patients with moderate to severe
chronic low back pain,24,30 osteoarthritis pain,23,30 or
pain related to DPN,40,57 and the results of 2 recent
Phase IIIb studies of tapentadol PR in patients with
severe chronic osteoarthritis knee pain38 or low back
pain with or without a neuropathic component.37 The
mean (SD) doses of tapentadol PR taken after the
initial titration periods in each study are shown in
Table I; mean total daily doses (TDDs) in the Phase
IIIb studies37,38 were lower than those observed in the
Phase III studies.23,24,30,40 This difference was possibly
due to the permitted use of concomitant WHO step I
analgesics or coanalgesics during study treatment
(which is more representative of clinical practice) in
the Phase IIIb studies,37,38 whereas no concomitantJanuary 2015analgesics were permitted in the Phase III studies other
than paracetamol/acetaminophen, which was used as
a rescue drug.23,24,30,40 At these doses, tapentadol PR
was associated with effective and tolerable relief of
chronic pain.23,24,30,37,38,40
Efﬁcacy data were pooled from 3 similarly de-
signed, randomized, double-blind, Phase III studies
comparing tapentadol PR (100–250 mg bid) with
placebo and oxycodone hydrochloride CR (20–50
mg bid) in patients with moderate to severe, chronic
low back pain (1 study24) and chronic osteoarthritis
pain (2 studies23). Mean changes from baseline in pain
intensity (last observation carried forward [LOCF])
over time from that pooled analysis are shown in
Figure 2.29 Based on the change in mean pain intensity
(11-point numerical rating scale [NRS]) from baseline
for the overall 12-week maintenance period (LOCF),
tapentadol PR met the primary end point of showing
noninferior efﬁcacy, and even superior efﬁcacy based
on the outcome of a preplanned additional analysis, to
that of oxycodone CR (least-squares mean difference
for tapentadol PR vs oxycodone CR ¼ 0.2; 95% CI,
0.01–0.40; P ¼ 0.037 for superiority). Sensitivity
analyses using different methods of imputation (base-
line observation carried forward [BOCF], worst ob-
servation carried forward (WOCF), and modiﬁed
BOCF) also indicated that tapentadol PR provided
superior analgesic efﬁcacy to oxycodone CR
(Figure 3). Tapentadol PR also showed signiﬁcantly
greater improvements from baseline than oxycodone
CR for measures of health-related quality of life,
including the 36-item Short Form Health Survey
physical and mental component summary scores
(P o 0.001 for both comparisons) and all subscale
scores (P r 0.048 for all comparisons) except general
health (P ¼ 0.061; Figure 4). Similar results were
observed when efﬁcacy data were pooled from the97
Table I. Total daily doses (TDDs) of tapentadol PR in clinical studies. Data are given as mean (SD)
milligrams.
Study TDD
Phase III studies
Low back pain study24 381.8 (117.13)*
Osteoarthritis knee pain study23 357.9 (112.59)*
Diabetic peripheral neuropathy study40 418.6 (314.17)*
1-y tolerability study30 326.7 (120.23)†
Phase IIIb studies
Chronic low back pain with or without a neuropathic component study37 311.2 (123.85)‡
Chronic low back pain with or without a neuropathic component
(after conversion from previous WHO step III therapy) study45
322.8 (120.73)‡
Chronic osteoarthritis knee pain study38 256.9 (111.38)‡
Chronic osteoarthritis knee pain with or without a neuropathic component
(after conversion from previous WHO step III therapy) study56
232.7 (145.37)‡
Noninterventional study
Severe chronic pain study58 203.7 (102.40)§
PR ¼ prolonged release; WHO ¼ World Health Organization.
*Dose during the 12-week maintenance period.
†Dose during the 52-week study.
‡Dose at week 6 (the ﬁrst week after titration).
§Dose at the ﬁnal study visit.
Clinical Therapeutics2 studies in patients with moderate to severe chronic
osteoarthritis pain23 only. Based on the change in
mean pain intensity (11-point NRS) from baseline for0 1 2 3 4 5 6
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tapentadol PR showed superior analgesic efﬁcacy to
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Modified BOCF
WOCF
BOCF
LOCF
LSMD (95% CI)
Favors Oxycodone CR Favors Tapentadol PR
0.249
<0.001
<0.001
<0.001
0.037
P Value
Figure 3. Least-squares mean difference (LSMD)
(95% CI) for the change in pain inten-
sity (11-point numerical rating scale)
from baseline for the overall 12-week
maintenance period for tapentadol PR
versus oxycodone CR using different
imputation methods from a pooled
analysis of data from 3 Phase III studies
in patients with osteoarthritis knee pain
or low back pain.*,† BOCF ¼ baseline
observation carried forward; CI ¼ con-
fidence interval; CR ¼ controlled re-
lease; LOCF ¼ last observation carried
forward; PMI ¼ placebo mean imputa-
tion; PR ¼ prolonged release; WOCF ¼
worst observation carried forward.
*Based on pooled data from 3 rando-
mized, double-blind, placebo- and
active-controlled, 15-week, Phase III
studies of similar design in patients
with moderate to severe chronic low
back pain (1 study24) and osteoarthritis
knee pain (2 studies23). †Tapentadol
PR, n ¼ 975; oxycodone CR, n ¼ 996.
M.J. Sa´nchez del A´guila et al.for tapentadol PR vs oxycodone CR ¼ 0.72; 95%
CI, 0.50–0.94; P o 0.001). For that meta-analysis,
sensitivity analyses using different methods of impu-
tation (BOCF, WOCF, and modiﬁed BOCF) also
indicated that tapentadol PR provided superior an-
algesic efﬁcacy to oxycodone CR (Figure 5).
Beyond these clinical trials, the administration of
tapentadol PR in routine clinical practice has been
evaluated in a prospective, noninterventional trial.58
That trial included results from 3134 patients with
severe chronic back pain; osteoarthritis pain; pain
related to DPN, postherpetic neuralgia, stroke, or
trauma; tumor-related pain; and pain related to other
causes. Tapentadol PR was prescribed and titrated as
recommended in the package insert. At the end of the
observation period, the mean dose (203.7 mg) wasJanuary 2015lower than that used in the Phase III studies, likely due
to the permitted use of concomitant nonopioid analgesic
regimens during tapentadol PR treatment (Table I).58Initiation and Dosing of Tapentadol PR
Treatment in Special Populations
Initial doses of tapentadol PR may need to be
adjusted depending on certain patient-speciﬁc factors,
including age and comorbid medical conditions. In
general, no dose adjustment is needed for patients with
mild hepatic impairment, whereas treatment for patients
with moderate hepatic impairment should be initiated at
the lowest possible dose strength (tapentadol PR, 50 mg
or 25 mg [if available]) and should not be administered
more than once in a 24-hour period.33 This approach is
recommended because in patients with moderate hepatic
impairment, elevations in serum concentrations of
tapentadol have been observed compared with patients
with normal hepatic function.33 In patients with renal
impairment, no alteration has been observed in
tapentadol levels compared with patients with normal
renal function.33 Treatment with tapentadol PR is not
recommended in patients with severe renal or hepatic
impairment because it has not been studied in patients
with these conditions.33
The mean exposure (area under the curve) to
tapentadol has been found to be similar for elderly
patients (65–78 years old) and young patients (19–43
years old), with a 16% lower maximum concentration
in elderly patients than in young patients.33 In general,
no dose adjustment is necessary for elderly patients
treated with tapentadol PR. A favorable gastro-
intestinal tolerability proﬁle has been reported for
elderly patients (Z75 years of age) in a post hoc
analysis of pooled data from 3 similarly designed,
randomized, double-blind, Phase III studies that found
signiﬁcantly lower incidences of gastrointestinal
treatment-emergent adverse events (TEAEs) and gas-
trointestinal TEAE-related discontinuations with ta-
pentadol PR compared with oxycodone CR (Po 0.05
for both comparisons).59 In this respect, tapentadol
PR also offers a promising alternative to poorly
tolerated treatment options in practice. Because renal
or hepatic impairment is more likely for older patients,
these patients should be checked for potentially
related dose-limiting factors.
Tapentadol PR is currently not recommended for use
in a pediatric population.33 A pediatric development99
Ph
ysi
ca
l C
om
po
ne
nt
 Su
m
m
ar
yf
M
en
ta
l C
om
po
ne
nt
 Su
m
m
ar
yf
M
en
ta
l H
ea
lth
c
Ro
le-
Em
ot
ion
al
c
So
cia
l F
un
cti
on
ing
c
Vit
ali
ty
c
Ge
ne
ra
l H
ea
lth
e
Bo
dil
y P
ain
d
Ro
le-
Ph
ysi
ca
lc
Ph
ysi
ca
l F
un
cti
on
ing
b
LS
M
D
 fo
r 
Ta
pe
nt
ad
ol
 P
R
vs
 O
xy
co
do
ne
 C
R
–7
–6
–5
–4
–3
–2
–1
0
–2.4g
–5.8h
–3.8h
–1.1
–4.4h –4.3h
–3.1i
–1.8 j
–1.3h –1.3h
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Clinical Therapeuticsprogram for tapentadol is ongoing at the time of this
publication.
In summary, the favorable tolerability proﬁle for
tapentadol PR relative to other classic opioid analge-
sics allows for a simple titration schedule with
relatively rapid up-titration so that patients do not
need to remain at a low dose for an extended period.
The recommended dosing regimen and rapid titration
schedule for tapentadol PR (Figure 1) have been
successfully used in clinical studies23,24,30,40 and in a
noninterventional trial.58,60 This titration schedule
may facilitate earlier establishment of pain control
for patients with chronic pain, and the recommended
dose range (up to 500 mg/d) has been sufﬁcient to
control severe to very severe pain.
CONVERSION/SWITCHING FROM CLASSIC
STRONG OPIOIDS
Patients may need to switch opioid analgesics if their
pain does not respond to increasing doses of their
current opioid, if increasing doses of their current
opioid are associated with unmanageable adverse
effects, or if opioid switching may be associated with100other potential beneﬁts (eg, improved pharmacoki-
netic proﬁle, improved ease of administration).61
Opioid switching between opioid analgesics with
similar mechanisms of action may not yield long-
term improvements in tolerability or efﬁcacy.62–64
Given its improved tolerability proﬁle relative to the
classic opioid analgesics oxycodone CR23,24,29,30,40
and morphine CR42 and its proposed lower cross-
tolerance for analgesia due to a unique mechanism
of action, tapentadol PR may offer a better option
than classic opioid analgesics when converting pa-
tients from a previous strong opioid to a new
analgesic.
When switching from a previous strong opioid
analgesic to tapentadol, the type and dose of the
previous opioid analgesic should be considered in
selecting a starting dose of tapentadol PR, which
may be higher than that required for opioid-naive
patients.33 Recommended starting doses of tapentadol
PR based on previous opioid doses are summarized in
Tables II and III. A dose reduction is typically
recommended when switching from one opioid to
another.65,66 When switching opioids, it may beVolume 37 Number 1
PMI
Modified BOCF
WOCF
BOCF
LOCF
0.102
<0.001
<0.001
<0.001
0.002
–1.2 –1.0 –0.8 –0.6 –0.4 –0.2 0 0.2 0.4 0.6 0.8 1.0 1.2
LSMD (95% CI)
Favors Oxycodone CR Favors Tapentadol PR
P Value
Figure 5. Least-squares mean difference (LSMD)
(95% CI) for the change in pain inten-
sity (11-point numerical rating scale)
from baseline for the overall 12-week
maintenance period for tapentadol PR
versus oxycodone CR using different
imputation methods from a pooled
analysis of data from 2 Phase III studies
in patients with osteoarthritis knee
pain.*,† BOCF ¼ baseline observation
carried forward; CI ¼ confidence inter-
val; CR ¼ controlled release; LOCF ¼
last observation carried forward; PMI,
placebo mean imputation; PR ¼ pro-
longed release; WOCF ¼ worst obser-
vation carried forward. *Based on
pooled data from 2 randomized, dou-
ble-blind, placebo- and active-con-
trolled, 15-week, Phase III studies of
similar design in patients with moder-
ate to severe chronic osteoarthritis knee
pain.23 †Tapentadol PR, n ¼ 663;
oxycodone CR, n ¼ 673.
Table II. Dosage conversions for the start of
therapy to achieve an equianalgesic
dose when switching from strong
opioids: dosing conversions used in
Phase IIIb conversion studies. Repro-
duced with permission.56
Mean MED (mg/d)*
Starting Dose of
Tapentadol PR per Day
r100 50 mg BID†
101–160 100 mg BID†
4160 150 mg BID†
MED ¼ morphine-equivalent dose; PR ¼ prolonged
release.
*Includes all formulations of all strong opioids taken.
†Approximately every 12 hours.
M.J. Sa´nchez del A´guila et al.difﬁcult to ﬁnd the ideal dose of the new opioid
analgesic in terms of balancing the potential for provid-
ing too high of a dose, which may exacerbate potential
opioid-related adverse effects, and underdosing, which
may increase the risk of pain peaks or withdrawal
symptoms. For tapentadol PR, which exerts less opioid
receptor activation than conventional opioids owing to
its MOR and NRI mechanisms of action, it may be
considered to not reduce the dose by 430% of the
calculated equianalgesic dose of the previous opioid (if
that dose is within the therapeutic dose range of
tapentadol PR) because this may minimize the risk of
withdrawal symptoms related to discontinuation of the
previous opioid. Generally, titration after conversion
from previous strong opioid analgesics should follow
the same schedule described in Section 2. Because of
tapentadol’s favorable tolerability proﬁle, it may beJanuary 2015possible to titrate tapentadol PR to doses above the
equianalgesic doses of previous opioids, thereby offering
the potential for added analgesia.
The successful rotation of patients from previous
strong (WHO step III) opioids to tapentadol PR has
been reported in 2 recent Phase IIIb studies45,56 in
patients with severe chronic low back pain or osteo-
arthritis pain who had responded to WHO step III
opioids but showed poor tolerability. The starting
doses in these 2 studies45,56 were based on the
morphine equivalent doses of all previous opioids used
(Table II). In the low back pain study,45 approximately
two-thirds of patients achieved comparable analgesia
as with their previous WHO step III analgesic on that
starting dose and required no dose increase, and
480% of patients in the osteoarthritis study56
achieved comparable analgesia as with their previous
opioid on the starting dose. After titration, most
patients in both studies (low back pain study,
80.9%45; osteoarthritis pain study, 94.3%56)
achieved at least comparable or better pain control
with tapentadol PR as with their previous WHO step
III analgesic. In the low back pain study,45 tapentadol
PR showed improvements in efﬁcacy and neuropathic
pain symptoms compared with the previous WHO
step III opioid, with signiﬁcant improvements from
baseline (when patients were receiving previous WHO
step III therapy) to weeks 6 and 12 of the study (on
tapentadol PR) in mean pain intensity and neuropathic101
Table III. Dosage conversions for the start of therapy to achieve an equianalgesic dose when switching from
strong opioids: European dosing recommendations.
Opioid
Starting Dose of Tapentadol PR (mg/d)
50 BID 100 BID 150 BID 200 BID 250 BID
Oxycodone, oral
(mg/d)*
39 40–59 60–79 80–99 At higher dosages (depending on
previous opioid daily dose), one
might consider starting with the
maintenance dose of 250 mg/d BID.
Tapentadol PR total daily doses
4500 mg have not been studied
and are, therefore, not
recommended.
Morphine, oral
(mg/d)
79 80–119 120–159 160–199
Hydromorphone,
oral (mg/d)
11 12–15 16–19 20–27
Fentanyl, transdermal
(μg/h)
37.4 37.5–49.9 50–74 75–86
Buprenorphine,
transdermal (μg/h)
34 35–52.4 52.5–69 70–87.4
CR ¼ controlled release; PR ¼ prolonged release.
*The dose conversion ratio for tapentadol PR versus oxycodone CR was derived from clinical Phase III studies (tapentadol:
oxycodone 5.1) and is in line with equianalgesic information from a Phase IIIb trial.56
Clinical Therapeuticspain symptoms (P o 0.05 for all comparisons). Equi-
analgesic ratios of tapentadol PR and WHO step III
opioids in the Phase IIIb study in patients with severe
chronic low back pain are summarized in Table IV.45
Although the number of patients used to determine
each of these equianalgesic ratios was relatively small,
the equianalgesic ratio determined for tapentadol PR
to oxycodone CR in this Phase IIIb study45 was in line
with that observed in a pooled analysis of data from
randomized, double-blind, placebo- and active-
controlled, Phase III studies comparing tapentadol
PR and oxycodone CR,29 and was conﬁrmed in a
second Phase IIIb study of similar design.56 In both
studies,45,67 the prevalence of TEAEs that were re-
ported as the reason for switching from previous
WHO step III therapy (most commonly constipation
and nausea) decreased with tapentadol treatment
(Figure 6). Approximately 6% of patients in the osteo-
arthritis study45 and 20% of patients in the low back
pain study4 experienced drug withdrawal syndrome,
largely on switching from their previous strong opioid
to tapentadol PR. Withdrawal symptoms on opioid
switching are relatively common, and the rates of
withdrawal observed on switching from a previous
WHO step III opioid to tapentadol PR in these
2 studies45,67 are notably lower than those observed102in a study of patients with chronic nonmalignant pain
who were switched from one strong opioid to another.68
In that study,68 the rate of withdrawal was 32% for
patients switching from one PR opioid to another and
44% for patients switching from an immediate-release
(IR) opioid to a PR opioid.68 Withdrawal symptoms
occurring on opioid switching may be addressed by
coadministration of another opioid analgesic, preferably
the IR formulation of the previous opioid.63 For con-
comitant use of IR opioids with tapentadol PR for
breakthrough pain, please refer to the “Concomitant
Analgesics and Coanalgesics” subsection later herein.
Findings from the previously described noninter-
ventional trial58 provided further evidence for the
successful rotation of patients directly from a
previous strong opioid analgesic to tapentadol PR.
At the time of this trial, a reﬁned conversion table,
based on the results of Phase IIIb studies and early
practical postlaunch experience, was used. In this non-
interventional trial,58 1331 patients had previously
received a WHO step III analgesic; the most common
reasons that patients switched to tapentadol PR from
their previous strong opioid analgesic were a lack of
efﬁcacy, poor quality of life, and poor tolerability. The
mean (SD) dose of tapentadol PR used by this subset
of patients at the end of the study was 227.8 (108.8) mg.Volume 37 Number 1
Table IV. Equianalgesic ratios of tapentadol to
WHO step III opioids. Adapted with
permission.45,*
WHO Step III
Opioid† No.
PR
Formu-
lations‡
PR and IR
Formu-
lations§
Buprenorphine 24|| 170:1 210:1
Fentanyl 22 224:1 251:1
Hydromorphone 8 8.3:1 10.5:1
Morphine 14 2.9:1 3.0:1
Oxycodone 35¶ 4.3:1 5.3:1
IR ¼ immediate release; PR ¼ prolonged release;
WHO ¼ World Health Organization.
*Based on data from a Phase III study in which patients
with severe chronic low back pain with or without a
neuropathic component switched directly from previous
strong (WHO step III) opioid therapy to tapentadol PR
use.45
†Buprenorphine was administered transdermally or as an
IR formulation (sublingually); fentanyl was administered
transdermally; all other WHO step III opioids were
administered orally.
‡Equianalgesic dose ratios calculated for tapentadol PR
to PR formulations of WHO step III opioids.
§Equianalgesic dose ratios calculated for tapentadol PR
plus tapentadol IR to PR plus IR formulations of WHO
step III opioids.
||PR formulations, n ¼ 21.
¶PR formulations, n ¼ 34.
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Figure 6. Reduction in the prevalence of gastro-
intestinal and nervous system adverse
events reported as the reason for
switching from strong opioid therapy
to tapentadol PR therapy in patients
with (A) severe chronic low back pain
with or without a neuropathic compo-
nent45 and (B) severe chronic osteo-
arthritis knee pain.67 The prevalence of
these adverse effects for previous
strong opioids was summarized during
the week before starting tapentadol PR
treatment, when patients were still on
their previous opioid regimen, and the
prevalence of these adverse effects for
tapentadol PR was summarized during
the last week of a 12-week treatment
period with tapentadol PR. PR ¼
prolonged release.
M.J. Sa´nchez del A´guila et al.Most patients (480%) continued tapentadol PR
treatment after the end of the 3-month observation
period, and 88% of patients achieved their treat-
ment goal with tapentadol PR. Based on the results of
this trial58 and further reﬁned practice-related experi-
ence, a further reﬁned conversion table was developed
in Europe (Table III).
In summary, the efﬁcacy and tolerability proﬁle of
tapentadol PR make it a favorable option for patients
who need to be switched from a previous strong opioid
analgesic owing to poor tolerability or a lack of efﬁcacy
at the current doses. Evidence from Phase IIIb stud-
ies45,67 and a noninterventional trial support the ease of
successfully switching patients directly from a previous
strong opioid analgesic to tapentadol PR, even for
those who had achieved adequate analgesia (but
experienced poor tolerability) on their previous opioid.January 2015STOPPING TAPENTADOL PR TREATMENT
Patients taking opioid analgesics for chronic non-
cancer pain may experience withdrawal as a symptom
of physical dependence after cessation of therapy.69,70
Withdrawal symptoms may represent a signiﬁcant
problem for patients who need to discontinue their
opioid treatment. As an analgesic with MOR agonist
activity, tapentadol PR may be associated with the103
Clinical Therapeuticspotential for withdrawal symptoms after abrupt dis-
continuation.33
To determine the extent of any possible opioid
withdrawal after cessation of tapentadol PR treat-
ment, the occurrence of withdrawal after abrupt
discontinuation of tapentadol PR has been evaluated
in a 1-year, open-label, Phase III tolerability study30;
in a 1-year, open-label extension study including
patients who had previously taken tapentadol PR for
1 year during the tolerability study71; and in a pooled
analysis of 9 randomized, multiple-dose Phase II or III
studies in patients with chronic osteoarthritis pain,
low back pain, or pain related to DPN of up to
1 year.72 The Clinical Opiate Withdrawal Scale in the
1-year tolerability study30 and open-label extension
study71 found that most patients (Z88%) who were
treated with tapentadol PR for r2 years experienced
no opioid withdrawal after abrupt discontinuation of
treatment and that all occurrences of withdrawal were
of mild to moderate intensity. Clinical Opiate
Withdrawal Scale results from the pooled analysis72
found that most patients (85% [972 of 1145])
experienced no opioid withdrawal and that all
occurrences of opioid withdrawal were of mild to
moderate intensity after discontinuation of tapentadol
PR (mean TDD, 260 mg).
In summary, these results indicate that withdrawal
after discontinuation of tapentadol PR treatment is
minimal on abrupt cessation. Nevertheless, to mini-
mize the possibility that respective symptoms will
occur, tapentadol PR doses may be tapered gradually
rather than being stopped abruptly.33
LONG-TERM TREATMENT WITH
TAPENTADOL PR
Patients with chronic pain often require long-term
analgesic treatment.73 The use of opioid analgesics to
manage chronic noncancer pain is increasing74;
however, evidence supporting the long-term efﬁcacy
and tolerability of these agents is frequently lacking.73
In addition to the generally favorable efﬁcacy and
tolerability proﬁle reported for tapentadol PR in
patients with chronic pain for approximately 3 to
4 months,23,24,29,36–44 tapentadol PR has been found
to be effective and well tolerated for up to 2 years in
patients with chronic osteoarthritis knee pain or low
back pain.30,71,75
Findings from the previously mentioned 1-year,
open-label, Phase III tolerability study of tapentadol104PR versus oxycodone CR30 and the 1-year, open-label
extension study support the well-tolerated and effec-
tive use of tapentadol PR for up to 2 years. Among
patients who received tapentadol PR during the 1-year
tolerability study30 and continued treatment in the
1-year extension study,76 mean pain intensity (11-point
NRS; LOCF) decreased from a baseline score of 7.6 to
3.4 within 4 weeks of treatment and then remained
relatively constant during the remaining up to 2 years
of treatment (Figure 7). After the initial titration
period, mean TDDs of tapentadol PR remained
relatively stable, as did mean pain intensity scores,
for up to 2 years of treatment, indicating that
tapentadol PR treatment was not associated with
acquired tolerance.30,76 During the initial 1-year
tolerability study,30 mean TDDs of oxycodone CR
remained relatively stable after the titration period, as
did mean pain intensity scores. For the overall popu-
lation in the initial tolerability study,30 tapentadol PR
treatment was associated with clinically meaningful
improvements77,78 in measures of health-related qual-
ity of life during 1 year of treatment; these improve-
ments were maintained during the second year of
treatment for patients who continued tapentadol PR
treatment in the extension study.76 Tapentadol PR
was well tolerated, with a particularly favorable
gastrointestinal tolerability proﬁle, during up to
2 years of treatment.30,76 During the initial 1-year
tolerability study,30 22.1% of patients in the tapentadol
extended-release group and 36.8% of patients in the
oxycodone CR group experienced TEAEs leading to
study discontinuation. The overall incidence of gastro-
intestinal TEAEs leading to discontinuation was lower
in the tapentadol PR group (8.6%) than in the oxy-
codone CR group (21.5%), as were the incidences of
the individual gastrointestinal TEAEs of nausea (3.4%
vs 12.1%), constipation (1.6% vs 7.2%), and vomiting
(2.6% vs 6.7%).30 For the overall population in the
initial tolerability study,30 the incidences of the
following gastrointestinal adverse events were lower
with tapentadol PR than with the active comparator,
oxycodone CR: nausea (18% vs 33%), vomiting (7%
vs 14%), and constipation (23% vs 39%). The
incidences of the most common TEAEs (incidence
Z5%) reported by patients who received up to
2 years of tapentadol PR treatment are summarized
in Table V.
In summary, these results indicate that tapentadol
PR is well tolerated and effective during up to 2 yearsVolume 37 Number 1
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M.J. Sa´nchez del A´guila et al.of treatment in patients with chronic pain,30,76 with
no development of acquired tolerance to the analgesic
effects of tapentadol over time (based on evaluations
of mean pain intensity and mean TDDs over time).
USE OF TAPENTADOL IR IN ADDITION TO
TAPENTADOL PR FOR ACUTE PAIN EPISODES
Tapentadol IR is indicated for the relief of moderate
to severe acute pain in adults, which can be ad-
equately managed only with opioid analgesics.79
Tapentadol IR has been used on top of tapentadol
PR treatment for acute pain episodes or for the relief
of withdrawal symptoms after direct conversion from
previous strong opioid analgesics in several Phase IIIb
studies.37,38,45,56 The results of these studies suggest
the effectiveness and tolerability of tapentadol IR on
top of tapentadol PR in patients with low back pain
with or without a neuropathic pain component37,45
and in those with osteoarthritis knee pain.38,56
In 4 open-label, Phase IIIb studies in patients with
severe low back pain or osteoarthritis knee
pain,37,38,38,45 tapentadol IR (50 mg, twice daily or
less; Z4 hours apart) was permitted for acute pain
episodes or for the relief of withdrawal symptoms
occurring after the discontinuation of previous opioid
analgesics; the total tapentadol doses (including PR and
IR formulations) could not exceed 500 mg/d.37,38,45,56
After the tapentadol PR doses had stabilized, mostJanuary 2015patients (55% to 89%) did not require additional
analgesia with tapentadol IR, and the mean daily
doses of tapentadol IR used were relatively low (6.7–
24.6 mg).37,38,45,56 In all 4 studies,37,38,45,56 tapenta-
dol treatment, which included a combination of
tapentadol PR and IR, was well tolerated and effec-
tive. The data collected on the use of tapentadol IR for
the treatment or prevention of withdrawal symptoms
after discontinuation of previous opioids in these
trials37,38,45,56 were not sufﬁcient to allow for a
detailed analysis.
In summary, these results suggest that the use of
tapentadol IR on top of tapentadol PR could be a
feasible option for addressing particularly acute pain
episodes.37,38,45,56 Both the IR and PR formulations of
tapentadol may not be available in all countries. In
those cases, it may be possible to use other IR opioids
(eg, morphine, oxycodone) for the management of
acute pain episodes or withdrawal symptoms based on
the positive results observed with tapentadol IR on
top of tapentadol PR.
USE OF CONCOMITANT MEDICATIONS
WITH TAPENTADOL PR
Pharmacokinetic Interactions
Patients with severe chronic pain may have comor-
bid conditions that necessitate the use of concomitant
medications. Tapentadol is largely metabolized by105
Table V. TEAEs reported by Z5% of patients
who received up to 2 years of
treatment with tapentadol PR
(tolerability population [n ¼ 249]).76,*
System Organ Class
TEAEs, No. (%)
Tapentadol PR
(n ¼ 249)
Gastrointestinal disorders 162 (65.1)
Constipation 73 (29.3)
Nausea 51 (20.5)
Dry mouth 35 (14.1)
Diarrhea 34 (13.7)
Vomiting 26 (10.4)
Infections and infestations 149 (59.8)
Nasopharyngitis 35 (14.1)
Inﬂuenza 32 (12.9)
Upper respiratory tract infection 30 (12.0)
Sinusitis 24 (9.6)
Urinary tract infection 24 (9.6)
Bronchitis 17 (6.8)
Viral gastroenteritis 16 (6.4)
Nervous system disorders 132 (53.0)
Headache 51 (20.5)
Dizziness 39 (15.7)
Somnolence 34 (13.7)
Musculoskeletal and connective
tissue disorders
82 (32.9)
Arthralgia 23 (9.2)
Muscle spasms 13 (5.2)
Injury, poisoning, and procedural
complications
81 (32.5)
Contusion 14 (5.6)
Psychiatric disorders 75 (30.1)
Insomnia 35 (14.1)
Anxiety 20 (8.0)
Depression 14 (5.6)
General disorders and
administration site conditions
64 (25.7)
Fatigue 24 (9.6)
Respiratory, thoracic, and
mediastinal disorders
50 (20.1)
Pharyngolaryngeal pain 13 (5.2)
Vascular disorders 41 (16.5)
Hypertension 27 (10.8)
PR ¼ prolonged release; TEAE ¼ treatment-emergent
adverse event.
*Incidences are based on the number of patients experi-
encing Z1 adverse event, not on the number of events.
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106phase 2 glucuronidation, a high-capacity/low-afﬁnity
system that would not be inhibited at clinically relevant
concentrations, suggesting a low potential for interactions
related to phase 2 metabolism.33 Furthermore, tapentadol
does not inhibit or induce cytochrome P450 enzymes,20
and tapentadol shows low plasma protein binding
(20%).33 Therefore, the occurrence of pharmaco-
kinetic drug-drug interactions related to the cytochrome
P450 system or displacement from protein binding is
unlikely.33 Tapentadol has no active metabolites and is
not a prodrug that is activated by metabolism,16 resulting
in a reliable pharmacokinetic proﬁle and an analgesic
proﬁle that is not altered by metabolic factors. Accord-
ingly, 2 randomized, open-label, drug-drug interaction
studies reported that when tapentadol was administered
concomitantly with the commonly used nonopioid an-
algesics paracetamol, acetylsalicylic acid, and naproxen,
no clinically relevant changes were observed in its
pharmacokinetic properties.80 Results of other studies
suggest no evidence of clinically relevant changes in the
pharmacokinetic properties of tapentadol administered
with metoclopramide, probenecid, or omeprazole.81–83
Pharmacodynamic Interactions
As for all combinations of centrally acting drugs,
certain precautions are recommended when dosing
tapentadol PR with other CNS-active medications.
The concomitant use of CNS-depressant drugs, in-
cluding benzodiazepines, antipsychotics, H1 antihist-
amines, opioids, and alcohol, may, in general, result in
an increase in sedative effects, respiratory depression,
or impaired vigilance.33 Despite an improved CNS
tolerability proﬁle, such pharmacodynamic inter-
actions may also occur with tapentadol, and care
should be taken. In a pooled analysis of data from
11 randomized placebo-controlled trials84 that evaluated
the tolerability of tapentadol used concomitantly with a
selective serotonin reuptake inhibitor or serotonin
norepinephrine reuptake inhibitor, the TEAEs ob-
served were in line with those expected with tapen-
tadol treatment based on the population studied and the
labeling,33,79 and no clinically relevant drug-drug inter-
actions were identiﬁed.84 For further updated details,
reference should be made to the summary of product
characteristics for tapentadol PR.33
Concomitant Analgesics and Coanalgesics
The use of tapentadol PR concomitantly with
analgesics and coanalgesics has been evaluated in aVolume 37 Number 1
M.J. Sa´nchez del A´guila et al.variety of studies.36–38,42,45,56 The concomitant use of
WHO step I analgesics and coanalgesics was permit-
ted in the 4 previously described open-label, Phase IIIb
studies of tapentadol PR in patients with low back
pain with or without a neuropathic pain compo-
nent37,45 or with osteoarthritis knee pain.38,56 Across
all 4 studies,37,38,45,56 concomitant coanalgesics were
taken by 14.3% to 54.4% of patients and concom-
itant WHO step I analgesics were taken by 55.6% to
64.5% of patients. Despite the relatively high percen-
tages of patients taking WHO step I analgesics or
coanalgesics, the tolerability proﬁle observed in these
studies37,38,45,56 for tapentadol PR was generally
better than that observed in randomized, controlled,
Phase III studies23,24,40 that did not allow additional
analgesics or coanalgesics, indicating that the con-
comitant use of WHO step I analgesics or coanalgesics
did not have a negative effect on the tolerability of
tapentadol PR but also reﬂecting the lower mean
doses of tapentadol PR used in Phase IIIb studies. In
addition, morphine IR42,85,86 and oxycodone IR86
were permitted for the treatment of breakthrough
pain concomitantly with tapentadol PR in Phase III
studies in patients with moderate to severe chronic
malignant tumor–related pain. In those studies,42,85,86
tapentadol PR used concomitantly with morphine IR
and oxycodone IR was well tolerated. Although only
the concomitant use of morphine IR and oxycodone
IR for breakthrough pain has been evaluated, these
ﬁndings suggest that other IR opioids could be safely
used as well.
In a randomized, double-blind, Phase IIIb study in
patients with severe low back pain with a neuropathic
component,36 the analgesic efﬁcacy of a combination
of tapentadol PR (300 mg/d) and pregabalin (300 mg/d)
was comparable with that of tapentadol PR (500 mg/d),
and the incidence of the composite of dizziness and/or
somnolence was signiﬁcantly lower with tapentadol
PR monotherapy (16.9%) than with the combination
of tapentadol PR and pregabalin (27.0%; P ¼
0.0302). Still, incidences of the most common
TEAEs in the combination arm were relatively low
compared with the rates of adverse effects observed in
historical trials of combinations of opioids and
coanalgesics.14,15 Furthermore, the rate of adverse
event–related discontinuations remained comparable
in both treatment groups (tapentadol PR monother-
apy, 7.8%; tapentadol PR plus pregabalin combina-
tion therapy, 7.5%). Taken together, these resultsJanuary 2015suggest that combination therapy with tapentadol
PR and pregabalin was well tolerated and effective
and that tapentadol may be a more favorable and
complementary combination partner than pure strong
opioid agonists.36
Findings from the previously described prospective
noninterventional trial60 in patients with severe
chronic pain who were receiving tapentadol PR
during routine treatment by a general practitioner
or internist provided further support for the tolerable
use of concomitant analgesics with tapentadol PR. In
that study,60 concomitant analgesics were taken with
tapentadol PR by 48.4% of patients (strong opioids,
3.6%; weak opioids, 6.4%; nonopioids, 44.7%) at
the ﬁnal visit. Treatment was well tolerated, with
adverse drug reactions reported for only 7% of
patients.60
In summary, the results of these studies36–38,45,56,60,80,84
suggest that tapentadol PR has a low potential for
pharmacokinetic drug-drug interactions. Pharmacoki-
netic drug-drug interactions mediated by cytochrome
P450 pathways20 or plasma protein binding are
unlikely to occur with tapentadol PR.33 There is a
potential for pharmacodynamic interactions with
CNS-active drugs (see the summary of product char-
acteristics for full information).33 When tapentadol
PR has been administered with centrally acting
analgesics and coanalgesics,37,38,45,56 selective seroto-
nin reuptake inhibitor– or serotonin norepinephrine
reuptake inhibitor–type antidepressants, or anticon-
vulsants,33,36,79,84 the tolerability proﬁle has been
found to be comparable with that of tapentadol PR
alone, in line with the subpopulation studied. In
addition, a combination of tapentadol PR and pre-
gabalin36 was found to have a better tolerability
proﬁle compared with historical trials of other
opioid analgesics and coanalgesics.14,15 Taken as a
whole, these results indicate that tapentadol PR may
be safely coadministered with many other medica-
tions.
ABUSE AND DIVERSION
Abuse and diversion are major concerns for physicians
prescribing long-term opioid analgesics for the man-
agement of chronic noncancer pain.87–89 An abuse
liability trial in opioid-experienced patients versus oral
hydromorphone that was early in the clinical develop-
ment of tapentadol reported a similar liking potential
for oral tapentadol. In the United States and Europe,107
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Clinical Therapeuticstapentadol is considered a scheduled substance33,35; in
the United States, the Food and Drug Administration
has implemented a Risk Evaluation and Mitigation
Strategy for controlled substances to improve pre-
scribing practices and reduce drug diversion.90 A
tamper-resistant formulation of tapentadol PR (which
is resistant to crushing and forms a gel when com-
bined with small volumes of liquid) is available in the
United States.91
Although caution is warranted when prescribing
tapentadol PR to patients for whom there is a concern
about an elevated risk of drug misuse, abuse, addic-
tion, or diversion,33 results of recent studies indicate a
low level of abuse for tapentadol in practice. In a
study92 that evaluated the rates of abuse and diversion
of tapentadol IR after its introduction to the US
market using data from a US surveillance system
(the Researched Abuse, Diversion, and Addiction-
Related Surveillance [RADARS] system93), rates of
tapentadol IR abuse and diversion were low during
the ﬁrst 24 months after its introduction (Figure 8).92
Drug diversion rates were found to be low when either
population and unique recipients of dispensed drug
denominators were used.92 During the ﬁrst 2 years
after its introduction, no tapentadol IR diversion was
reported during a 9-month period (from the third
quarter of 2009 to the second quarter of 2010).92 The
diversion rate per 1000 unique recipients of dispensed
drug for tapentadol IR was low (substantially lower
than that for oxycodone or hydrocodone) throughout
the 2-year evaluation period despite the increase in the
number of unique tapentadol IR recipients during that
time frame.92 Data from that same surveillance system
were used to evaluate the street value of selected
prescription opioids, including tapentadol, during the
fourth quarter of 2012; very few street price reports
were available for tapentadol during the quarter
surveillance period, indicating limited availability of
tapentadol in the illicit market. In that study,94
opioids with a single mechanism of action had
higher street values than drugs with 41 mechanism
of action, including tapentadol.94 In a separate
study95 evaluating the rate of abuse of tapentadol IR
among US college students during the 2 years after its
launch in 2009, the rate of nonmedical use of
tapentadol IR was low (7 times lower than that
of oxycodone and 9 times lower than that of
hydrocodone) and declined during the 2-year period
despite increasing pharmacy sales. The low rate of108tapentadol misuse was also observed in a recent
retrospective cohort study,96 which found that the
risk of opioid doctor shopping was 43 times more
likely for patients treated with oxycodone than for
those treated with tapentadol.96
These ﬁndings from early clinical experience with
tapentadol suggest that it is associated with low rates
of abuse and diversion in practice. The potential for
abuse and addiction with tapentadol PR should be
considered, however, for patients for whom there is a
concern about an increased risk of misuse, abuse,
addiction, or diversion.33 Further data on abuse and
diversion of tapentadol need to be collected and
analyzed. If the currently observed proﬁle is
maintained, tapentadol may offer a safer option in
this respect for patients requiring strong analgesic
therapy for their chronic pain.
SUMMARY AND CONCLUSIONS
Tapentadol PR, which represents a proposed new
class of centrally acting analgesic with 2 mechanisms
of action, MOR agonism and NRI,16,17 has been in
practical use for Z3 years in various countries.
Tapentadol PR, which has been associated with
improvements in pain and quality of life for patientsVolume 37 Number 1
M.J. Sa´nchez del A´guila et al.with and without a neuropathic component to their
chronic pain, may provide clinically meaningful bene-
ﬁts over classic opioid analgesics for the long-term
management of severe chronic pain. Furthermore,
tapentadol PR treatment has been associated with
improvements in neuropathic pain symptoms for
patients with neuropathic pain only.37,45 Tapentadol
PR also has an improved tolerability proﬁle, partic-
ularly gastrointestinal tolerability, compared with
other classic opioid analgesics,23,24,29,30,40,42 which
may improve patient adherence to treatment and,
consequently, result in sustained pain relief. These
advantages regarding tolerability and efﬁcacy over
other opioid analgesics suggest that tapentadol PR
may provide a preferred option for managing chronic
pain in patients in a clinical setting.
Tapentadol PR generally provides effective and
well-tolerated analgesia for the management of chronic
pain across a broad range of analgesic indica-
tions.23,24,29,30,37,38,40,45,56,57 Evidence from practice-
related surveillance systems suggests a low rate of
abuse in clinical practice.92,95 The favorable efﬁcacy
and tolerability proﬁles of tapentadol PR and the low
risk of pharmacokinetic drug-drug interactions, with
fewer treatment discontinuations, may simplify use in
clinical practice. Full details regarding the prescription
and administration of tapentadol PR are available in
the summary of product characteristics.33
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